Week of August 29, 2011: Valeant Agrees to Acquire Afexa Life Sciences; Merck KGaA Names Robert Yates President of Millipore Division; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of August 29, 2011: Valeant Agrees to Acquire Afexa Life Sciences; Merck KGaA Names Robert Yates President of Millipore Division; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Company Notes

Bend Research, a CDMO, and the CRO Xcelience have formed a collaboration to provide oral solid-solubilization formulation solutions and expedited clinical-supply manufacturing in combined programs.

EMD Millipore, the life-sciences division of Merck KGaA, has acquired the CDMO Amnis. The transaction is subject to regulatory approvals and closing is expected to occur in the fourth quarter of 2011. The terms of the transaction were not disclosed.

The biopharmaceutcial company Icagen sent a letter to shareholders on Aug. 29, 2011, reaffirming the board of directors’ unanimous recommendation to accept the $6-per-share bid from Pfizer. The board received a letter from Pfizer on Aug. 26, 2011, that their proposal of $6 per share was their best and final offer, and that the offer was scheduled to expire at the end of Aug. 31, 2011.

Novo Nordisk has announced plans to build a new corporate center in Bagsværd, Denmark. The EUR 134-million ($193.4 million) project will feature two office buildings and house 1100 administrative employees. Groundbreaking will begin in October 2011, and completion is scheduled for the end of 2013.

Virginia Governor Bob McDonnell announced that Pfizer is selling its Henrico County, Virginia, manufacturing plant to the CMO Fareva, according to reports from various news sources. Fareva plans to invest $42 million into the facility, according to the reports.

Valeant Pharmaceuticals International, a specialty pharmaceutical company, has agreed to acquire the health-sciences company Afexa Life Sciences for approximately CAN 76 million ($77.6 million). Under the agreement, Afexa’s shareholders will receive CAN 0.71 per share in cash, and the company’s board of directors unanimously approved the offer. The deal is subject to customary closing conditions and regulatory approval.

People Notes

The American Association of Pharmaceutical Scientists (AAPS) has elected Dr. Anthony J. DeStefano, vice-president of General Chapters at the US Pharmacopeia, as the organization’s new president-elect. DeStefano will begin his three-year term in October at the 2011 AAPS Annual Meeting and Exposition in Washington, D.C.

Merck KGaA has named Robert Yates president of its Merck Millipore division, effective Sept. 1, 2011. He will report to Bernd Reckmann of Merck’s executive board, and will be responsible for the chemicals business sector, which includes the Merck Millipore and performance materials divisions.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here